• Saturday, 25 September 2021
*Take action on people without helmets and masks  *Kim Chou Guava plantations in Saang district tastes delicious and gaining customer support  *People still have 3 days off during the upcoming Pchum Ben festival, but must adhere to implement health measures  *Outcomes Of Virtual ASEAN-U.S. Foreign Ministers’ Meeting Released  *7,000 hectares of agricultural land in Banteay Meanchey province flooded by rain  *Boryakha Waterfall Resort in Pailin Province is an interesting place  *PM Calls For Understanding Over Suspension Of Kan Ben And Pchum Ben  *In battle of pumpkin spice vs. apple, one fall flavor has the edge  *Google CEO sought to keep Incognito mode issues out of spotlight, lawsuit alleges  *Bond Market Gets Reprieve From SEC Rule That Spooked Traders 

Chinese pharma company announces partnership with Canadian biotech firm

Chinese pharma company announces partnership with Canadian biotech firm

Chinese biopharmaceutical company Everest Medicines Ltd announced on Monday a strategic partnership with Canadian biotechnology company Providence Therapeutics Holdings Inc in an effort to develop mRNA COVID-19 vaccines.


Under the partnership, Everest has licensed rights to Providence's mRNA COVID-19 vaccine candidates in Asian emerging markets, including China, Southeast Asia, and Pakistan. The two parties will also establish a broad, strategic partnership to develop mRNA products globally, leveraging Providence's cutting-edge mRNA technology platform. 


Providence's lead mRNA COVID-19 vaccine candidate, which is currently in Phase 2 clinical trials, has demonstrated it is generally safe and well-tolerated and that the dosed subjects have high neutralization titers against the original strain of SARS-CoV-2 in an S protein-typed pseudovirus assay.


Everest and Providence will also enter into a 50/50 global collaboration, under which the parties will develop two additional prophylactic or therapeutic products. "We're thrilled to enter into this agreement as we work together to bring novel mRNA vaccines to patients in need around the world and help combat COVID-19 as well as other diseases," said Brad Sorenson, CEO of Providence Therapeutics. 


"In addition, this transaction structure with equity consideration and profit-sharing helps to align ongoing corporate interests between Everest and Providence, fostering future collaboration for innovative mRNA vaccine development across a range of disease areas.


"We believe mRNA vaccines for COVID-19 can provide another option in the armamentarium for fighting this pandemic. Gaining exclusive access to a unique and clinically validated mRNA technology platform through this strategic collaboration redoubles our commitment to accelerate global pharmaceutical innovation and deliver best-in-class medicines to people in China and other parts of Asia." 


"The platform will enhance our discovery efforts and will allow us to explore the promise of mRNA therapies for patients across a variety of key disease areas," said Kerry Blanchard, chief executive officer of Everest Medicines. 




Please select a date!


Subscribe to our mailing list to get the new updates!